The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety
Open accessAbstract
Levomilnacipran (LVM; F2695) is the more active enantiomer of the serotonin/norepinephrine (5-HT/NE) reuptake inhibitor (SNRI) milnacipran and is currently under development for the treatment of major depressive disorder. LVM was benchmarked against two other SNRIs, duloxetine and venlafaxine, in biochemical, neurochemical and pharmacological assays. LVM exhibited high affinity for human NE (Ki = 92.2 nM) and 5-HT (11.2 nM) transporters, and potently inhibited NE (IC50 = 10.5 nM) and 5-HT (19.0 nM) reuptake (human transporter) in vitro. LVM had 2-fold greater potency for norepinephrine relative to serotonin reuptake inhibition (i.e. NE/5-HT potency ratio: 0.6) and 17 and 27 times higher selectivity for NE reuptake inhibition compared with venlafaxine and duloxetine, respectively. LVM did not exhibit affinity for 23 off-target receptors. LVM (i.p.) increased cortical extracellular levels of 5-HT, and NE (minimal effective doses: MEDs = 20 and 10 mg/kg, respectively). In anti-depressive/anti-stress models, i.p. LVM diminished immobility time in the mouse forced swim (MED = 20 mg/kg) and tail suspension (MED = 2.5 mg/kg) tests, and reduced shock-induced ultrasonic vocalizations in rats (MED = 5 mg/kg). Duloxetine and venlafaxine were less potent (MEDs ≥ 10 mg/kg). At doses active in these three therapeutically-relevant models, LVM (i.p.) did not significantly affect spontaneous locomotor activity. In summary, LVM is a potent, selective inhibitor of NE and 5-HT transporters with preferential activity at the former. It is efficacious in models of anti-depressive/anti-stress activity, with minimal potential for locomotor side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Andrade, L., Caraveo‐anduaga, J. J., Berglund, P., Bijl, R. V., Graaf, R. D., Vollebergh, W., Dragomirecka, E., Kohn, R., Keller, M., Kessler, R. C., et al. (2003) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.138 · Cited by 1,068
Bymaster, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 717
Castagné, V., Moser, P., Roux, S., & Porsolt, R. D. (2011) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0810as55 · Cited by 702
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Relationship of neurotransmitters to the symptoms of major depressive disorder.
Nutt, D. (2008) · PubMed · Cited by 490
Castagné, V., Moser, P., Roux, S., & Porsolt, R. D. (2010) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0508s49 · Cited by 466
Stahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 458
Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor
Deecher, D. C., Beyer, C. E., Johnston, G., Bray, J., Shah, S., Abou-Gharbia, M., & Andree, T. H. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103382 · Cited by 381
Lapiz, M. D. S., & Morilak, D. A. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.09.031 · Cited by 325
Gartside, S. E., Umbers, V., Hajós, M., & Sharp, T. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb15919.x · Cited by 312
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308
Evidence of the dual mechanisms of action of venlafaxine
Harvey, A. T., Rudolph, R. L., & Preskorn, S. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.503 · Cited by 302
Porsolt, R. D., Brossard, G., Hautbois, C., & Roux, S. (2001) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0810as14 · Cited by 210
Dennis, T., L'Heureux, R., Carter, C., & Scatton, B. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-5347(25)00278-2 · Cited by 199
Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity
Vaishnavi, S. N., Nemeroff, C. B., Plott, S. J., Rao, S. G., Kranzler, J., & Owens, M. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.07.006 · Cited by 178
Moret, C., Charveron, M., Finberg, J. P. M., Couzinier, J. P., & Briley, M. (1985) · Neuropharmacology · doi:10.1016/0028-3908(85)90157-1 · Cited by 172
Relevance of Norepinephrine–Dopamine Interactions in the Treatment of Major Depressive Disorder
Mansari, M. E., Guiard, B. P., Chernoloz, O., Ghanbari, R., Katz, N., & Blier, P. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00146.x · Cited by 171
Millan, M. J., Gobert, A., Lejeune, F., Newman‐Tancredi, A., Rivet, J., Auclair, A., & Péglion, J.-L. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29415-5 · Cited by 162
Self-citationStress-induced vocalisation in adult animals. A valid model of anxiety?
Sánchez, C. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01277-9 · Cited by 161
Jelen, P., Soltysik, S., & Zagrodzka, J. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00321-2 · Cited by 155
Differential physiological effects of a low dose and high doses of venlafaxine in major depression
Debonnel, G., Saint-André, É., Hébert, C., de Montigny, C., Lavoie, N., & Blier, P. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006413 · Cited by 148
Effect of various classes of antidepressants in behavioral paradigms of despair
Kulkarni, S. K., & Dhir, A. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.05.002 · Cited by 126
Kihara, T., & Ikeda, M. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24303-8 · Cited by 123
Koch, S., Hemrick-Luecke, S. K., Thompson, L., Evans, D. C., Threlkeld, P. G., Nelson, D. L., Perry, K. W., & Bymaster, F. P. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00268-5 · Cited by 117
Turcotte, J., Debonnel, G., de Montigny, C., Hébert, C., & Blier, P. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00220-7 · Cited by 116
Beyer, C. E., Boikess, S., Luo, B., & Dawson, L. A. (2002) · Journal of Psychopharmacology · doi:10.1177/026988110201600403 · Cited by 114
Enhancement of Antidepressant Potency by a Potentiator of AMPA Receptors
Li, X., Witkin, J. M., Need, A. B., & Skolnick, P. (2003) · Cellular and Molecular Neurobiology · doi:10.1023/a:1023648923447 · Cited by 106
Chalon, S., Granier, L., Vandenhende, F., Bieck, P. R., Bymaster, F. P., Joliat, M. J., Hirth, C., & Potter, W. Z. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300209 · Cited by 95
The noradrenergic symptom cluster: clinical expression and neuropharmacology
Briley, M., & Blier, P. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s19613 · Cited by 74
Behavioral Assessment of Antidepressant Activity in Rodents
Porsolt, R. D., Castagn, V., & Moser, P. C. (2008) · Frontiers in neuroscience · doi:10.1201/noe1420052343.ch6 · Cited by 60
Weikop, P., Kehr, J., & Scheel-Krüger, J. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800311 · Cited by 57
Berrocoso, E., & Micó, J. A. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000236 · Cited by 54
Nogami, T., Takano, H., Arakawa, R., Ichimiya, T., Fujiwara, H., Kimura, Y., Kodaka, F., Sasaki, T., Takahata, K., Suzuki, M., et al. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001009 · Cited by 53
Bardin, L., Gregoire, S., Aliaga, M., Malfetes, N., Vitton, O., Ladure, P., Newman‐Tancredi, A., & Depoortère, R. (2009) · Neuroscience Research · doi:10.1016/j.neures.2009.10.009 · Cited by 49
Self-citationWong, D. T. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.10.1691 · Cited by 49
Berrocoso, E., & Micó, J. A. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008766 · Cited by 46
The chiral switch: the development of single enantiomer drugs from racemates.
Hutt, A. J., & Valentová, J. (2003) · Research Portal (King's College London) · Cited by 45
Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
Briley, M. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s13171 · Cited by 42
Andreasen, J. T., Nielsen, E. Ø., & Redrobe, J. P. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1560-1 · Cited by 22
Improvement of the noradrenergic symptom cluster following treatment with milnacipran
Briley, M., & Kasper, S. F. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s19615 · Cited by 19
Pharmacological evaluation of the isolated rat seminal vesicle preparation
Sharif, S. I., & Sd, G. (1986) · Journal of Pharmacological Methods · doi:10.1016/0160-5402(86)90006-9 · Cited by 17
Cited by
Talele, T. T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00472 · Cited by 1,023
Xue, W., Yang, F., Wang, P., Zheng, G., Chen, Y., Yao, X., & Zhu, F. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00490 · Cited by 288
Lukić, I., Getselter, D., Ziv, O., Oron, O., Reuveni, E., Koren, O., & Elliott, E. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0466-x · Cited by 273
Chirality of New Drug Approvals (2013–2022): Trends and Perspectives
McVicker, R. U., & O’Boyle, N. M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02239 · Cited by 255
Robinson, D. J., Coons, M., Haensel, H., Vallis, M., & Yale, J.-F. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.031 · Cited by 209
Metadata
- Authors
- Auclair, A. L., Martel, J. C., Assié, M. B., Bardin, L., Heusler, P., Cussac, D., Marien, M., Newman-Tancredi, A., O'Connor, J. A., & Depoortère, R.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 70
- Pages
- 338-347
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2134918392
- Cited by
- 263
- References
- 44
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.